Abstract
In patients with anti-Yo associated paraneoplastic cerebellar degeneration (PCD) neurological symptoms precede the diagnosis of the underlying cancer in about 60%. Ovarian carcinoma, breast cancer and other gynaecological malignancies are most frequently found as causative malignancies. Antitumour treatment should be applied in an early stage of disease. The identification of the tumour is a diagnostic challenge in many of these patients. In the first of two patients reported here a pelvic tumour was suggested after detection of a pathological lymph node and elevated tumour markers. The intraoperative findings appeared macroscopically normal during ovariectomy with adnexectomy. Not until microscopic examination of the resected tissue was performed was a tubal adenocarcinoma found. If intrapelvic gynaecological tumours are suspected a deliberate surgical exploration seems to be justified, but only after an intensive diagnostic investigation. To search for the underlying cancer in patients with paraneoplastic neurological disorders successive CT and [18F]-FDG-PET are widely recommended. Instead of this in the second reported patient whole-body dual-modality PET/CT was performed revealing enhanced uptake in three regions of the left thorax. By combining function and anatomy PET/CT was able to localise the lesions and characterise them as lymph node metastases of breast cancer. Diagnosis could be confirmed by subsequently executed needle biopsy. PET/CT seems to be highly applicable in the investigation of paraneoplastic disorders with unknown primary cancer. It may help in guidance of needle biopsy or to optimise the results of deliberate surgery and it provides whole-body tumour staging in a single session with higher diagnostic accuracy than PET alone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson NE, Rosenblum MK, Posner JB (1988) Paraneoplastic cerebellar degeneration: clinical-immunological correlations. Ann Neurol 24:559–567
Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, Bockisch A, Debatin JF, Freudenberg LS (2003) Non-Small Cell Lung Cancer: Dual-Modality PET/CT in Preoperative Staging. Radiology 229:526–533
Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanche JP, Confavreux C, Vighetto A, Renault-Mannel V, Michel D, Honnorat J (2000) [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol 48:105–108
Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, Altman H, Keidar Z, Israel O (2003) Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 44:1200–1209
Berner U, Menzel C, Rinne D, Kriener S, Hamscho N, Dobert N, Diehl M, Kaufmann R, Grunwald F (2000) Paraneoplastic syndromes: detection of malignant tumors using [18F]FDG-PET. Q J Nucl Med 47:85–89
Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L,Nutt R (2000) A combined PET-CT scanner for clinical oncology. J Nucl Med 41:1369–1379
Grisold W, Drlicek M, Liszka-Setinek U, Wondrusch E (1995) Anti-tumour therapy in paraneoplastic neurological disease. Clin Neurol Neurosurg 97:106–111
Keime-Guibert F, Graus F, Fleury A, Rene R, Honnorat J, Broet P, Delattre JY (2000) Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 68:479–482
Peterson K, Rosenblum MK, Kotanides H, Posner JB (1992) Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42:1931–1937
Posner JB (1995) Paraneoplastic syndromes. In: Posner JB (ed) Neurologic complications of cancer. FA, Davis, Philadelphia, pp 353–385
Rees JH, Hain SF, Johnson MR, Hughes RAC, Costa DC, Ell PK, Keir G, Rudge P (2001) The role of [18F]fluoro-2-deoxy-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 124:2223–2231
Rojas I, Graus F, Keime-Guibert F, Rene R, Delattre JY, Ramon JM, Dalmau J, Posner JB (2000) Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 55:713–715
Shams’ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, Vecht C, Sillevis Smitt P (2003) Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 126:1409–1418
Shinohara Y, Ohnuki Y, Yoshii F, Takahashi W, Onoe K, Takagi S (1998) Detection of primary tumor in paraneoplastic cerebellar degeneration by FDG-PET. Ann Neurol 43:684
Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, Bryer A, Diener HC, Massaquoi S, Gomez CM, Coutinho P, Ben Hamida M, Campanella G, Filla A, Schut L, Timmann D, Honnorat J, Nighoghossian N, Manyam B (1997) International Cooperative Rating Scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci 145:205–211
Voltz R (2002) Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol 1:294–305
Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH (2003) Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol 63:187–190
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Frings, M., Antoch, G., Knorn, P. et al. Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration. J Neurol 252, 197–201 (2005). https://doi.org/10.1007/s00415-005-0635-0
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00415-005-0635-0